Form 4: Fate Therapeutics Director Acquires Shares
Insider Transaction Report
William H. Rastetter, a Director at Fate Therapeutics, Inc., has acquired 25,000 shares of common stock through the exercise of a stock option.
Summary
- William H. Rastetter, a Director at Fate Therapeutics, Inc. (FATE), reported a transaction on May 5, 2026.
- He acquired 25,000 shares of common stock via the exercise of a stock option at a price of $1.69 per share.
- Following this transaction, Rastetter directly owns 36,331 shares.
- Additionally, he beneficially owns 146,821 shares indirectly through The Rastetter Family Trust and 459,272 shares indirectly through The Investment 2002 Trust.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral filing. While an insider acquisition can be positive, it's a standard transaction related to stock options and doesn't inherently signal new positive or negative developments for the company.
Positives
- Director acquisition of shares can signal confidence in the company's future prospects.
- The exercise of a stock option at a price of $1.69 suggests the current market price may be at or above this level, or that the option was exercised for strategic reasons.
- Significant indirect beneficial ownership through trusts indicates long-term commitment.
Future Outlook
No specific forward-looking statements or guidance are present in this Form 4 filing, which primarily reports past transactions.
Industry Context
StockSavvy.ai notes that insider transactions, such as this stock option exercise by a director, are common in the biotechnology sector. These filings provide transparency into executive and director confidence levels regarding their company's performance and valuation.
Stakeholder Impact
- Shareholders: This transaction provides transparency into director holdings and potential confidence signals, but does not directly impact share price or company operations in the short term.
- Employees: The exercise of stock options by management can be a positive indicator, potentially aligning executive interests with shareholder value.
- Creditors: No direct impact on creditors is indicated by this filing.
Key Dates
| Date | Description |
|---|---|
| 2010-09-02 | Date of The Rastetter Family Trust. |
| 2002-11-11 | Date of The Investment 2002 Trust. |
| 2017-01-01 | Date when the shares subject to the option vested and became exercisable (estimated based on '2017 Annual Meeting of Stockholders'). |
| 2026-05-05 | Transaction Date for the acquisition of common stock and exercise of stock option. |
| 2026-05-06 | Date of signature for the filing. |
Keywords
Form 4, SEC Filing, Insider Trading, Stock Option, Beneficial Ownership, Director, Fate Therapeutics, FATE, Common Stock, Trust
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.